Log in to search using one of your social media accounts:

 

Singing May Be Good Medicine for Parkinson's Patients

FRIDAY, Aug. 11, 2017 -- Singing? To benefit people with Parkinson's disease? It just may help, a researcher says. " We're not trying to make them better singers, but to help them strengthen the muscles that control swallowing and respiratory...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

CONCLUSION: Results indicated greater adhesiveness for the improved room temperature-stable formulation (PR2.3.1) vs. intermediate cold storage product (PR2.1.1) using the largest patch-size, with comparable safety and skin tolerability. PMID: 29461870 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Authors: Li DK, Liu FT, Chen K, Bu LL, Yang K, Chen C, Liu ZY, Tang YL, Zhao J, Sun YM, Wang J, Wu JJ Abstract Depressive symptoms and sensory dysfunction, such as reduction in visual and olfactory function, are common in Parkinson's disease (PD). Previous studies have suggested that depressive symptoms are associated with visual impairments and potentially with hyposmia in several types of mood disorders. However, the relationship between depressive symptoms and sensory dysfunction remains unclear in PD. To examine the association of depressive symptoms with color vision and olfactory function in PD, the authors c...
Source: Journal of Neuropsychiatry and Clinical Neurosciences - Category: Psychiatry Tags: J Neuropsychiatry Clin Neurosci Source Type: research
The Berwyn company's lead new drug candidate targets Alzhemier's and Parkinson's.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Publication date: Available online 21 February 2018 Source:Artificial Intelligence in Medicine Author(s): Stuart E. Lacy, Stephen L. Smith, Michael A. Lones Despite having notable advantages over established machine learning methods for time series analysis, reservoir computing methods, such as echo state networks (ESNs), have yet to be widely used for practical data mining applications. In this paper, we address this deficit with a case study that demonstrates how ESNs can be trained to predict disease labels when stimulated with movement data. Since there has been relatively little prior research into using ESNs for cla...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
Osmolex ER tablets, taken once daily in the morning, are a proprietary formulation containing immediate- and extended-release amantadine.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news
Abstract Lysosome-associated membrane glycoprotein 2 (lamp2) plays critical roles in chaperone-mediated autophagy (CMA) and macroautophagy. Its isoform lamp2a is decreased in Parkinson's disease (PD) substantia nigra. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most known common cause of late-onset PD; although LRRK2 is thought to regulate macroautophagy, the influence of LRRK2 mutations on lamp2 concentrations in the CNS is unknown. To examine this issue we compared lamp2 levels in cerebrospinal fluid (CSF) between sporadic PD (sPD) patients (n = 31), LRRK2 PD patients (n = 20), and...
Source: Brain Research - Category: Neurology Authors: Tags: Brain Res Source Type: research
Acorda Therapeutics (NSDQ:ACOR) said today that the FDA accepted the New Drug Application for its Inbrija investigational inhaled levodopa product designed for treating symptoms of OFF periods in patients with Parkinson’s disease who are taking carbidopa/levodopa regimens. The approval comes with a target date of October 5, 2018, the Ardsley, N.Y.-based company said. Read the whole story at our sister site, Drug Delivery Business The post Acorda Therapeutics wins FDA NDA nod for Inbrija appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Neurological Regulatory/Compliance Respiratory Acorda Therapeutics Source Type: news
Conditions:   Primary Parkinsonism;   Rehabilitation;   Kinematics;   Gait Disorders, Neurologic Interventions:   Other: Mental and Physical Practice;   Other: Physical Practice Sponsor:   Universidade Federal do Rio Grande do Norte Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson Disease Interventions:   Drug: Clarithromycin;   Drug: Placebo Sponsors:   Nicolaas Bohnen, MD, PhD;   National Institute of Neurological Disorders and Stroke (NINDS) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson Disease Interventions:   Drug: Lixisenatide;   Drug: placebo Sponsors:   University Hospital, Toulouse;   Cure Parkinson;   Réseau NS-Park;   EUCLID;   Sanofi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: General Medicine | Parkinson's Disease | Respiratory Medicine